Your Health, We Care
In the pursuit of health and recovery, rational use of drugs is a crucial part. Patients should be fully aware of the information about the drug, including but not limited to efficacy, dosage, and contraindications, before using any drug. Be sure to follow the doctor's guidance and do not increase or decrease the dose or change the drug at will, so as not to affect the efficacy or cause adverse reactions; Be aware of drug-drug interactions and avoid self-medication.
Fidaxomicin is a pharmacological agent specifically indicated for the treatment of Clostridium difficile associated diarrhea, suitable for adult and pediatric patients aged 6 month···【more】
Article source：Captain MedicineRelease date：2024-07-30Recommended：356
Fidaxomicin is primarily employed for the management of Clostridium difficile-associated diarrhea (CDAD). This medication exhibits low systemic absorption, lacks efficacy against d···【more】
Article source：Captain MedicineRelease date：2024-07-30Recommended：312
Anamorelinis a medication utilized in the treatment of specific ailments, and like all medications, Anamorelinmay potentially elicit some adverse effects. Patients should be well i···【more】
Article source：Captain MedicineRelease date：2024-07-30Recommended：262
Fidaxomicin is a pharmaceutical for the treatment of difficile-associated diarrhea (CDAD), indicated for adult and pediatric patients aged 6 months and older. CDAD is a gastrointes···【more】
Article source：Captain MedicineRelease date：2024-07-30Recommended：364
fidaxomicin, a pharmacological agent renowned for its efficacy against Clostridium difficile infection, operates by impeding the metabolic pathways of the bacterium, thus inhibitin···【more】
Article source：Captain MedicineRelease date：2024-07-30Recommended：306
Fidaxomicin is a pharmaceutical agent specifically designed to combat infections caused by Clostridium difficile. Prior to initiating treatment with Fidaxomicin, patients are advis···【more】
Article source：Captain MedicineRelease date：2024-07-30Recommended：271
Sotorasib, a targeted therapeutic agent for advanced non-small cell lung cancer (NSCLC) patients harboring the KRAS G12C mutation, exerts its efficacy by specifically inhibiting th···【more】
Article source：Captain MedicineRelease date：2024-07-09Recommended：392
Sotorasib, also known as Lumakras, is a targeted drug designed for patients with NSCLC carrying the KRAS G12C gene mutation. This medication inhibits the activity of the KRAS G12C ···【more】
Article source：Captain MedicineRelease date：2024-07-09Recommended：366
Sotorasibas a targeted therapeutic agent, is hailed as a milestone advancement in the medical field. As one of the pioneering small molecule inhibitors successfully targeting KRAS ···【more】
Article source：Captain MedicineRelease date：2024-07-09Recommended：368
Sotorasib is a targeted therapy for patients with advanced NSCLC with KRAS p.G12C mutations.KRAS geneis a key regulator during cell growth and division, when the p.G12C mutation oc···【more】
Article source：Captain MedicineRelease date：2024-07-09Recommended：406
Sotorasib represents a groundbreaking targeted therapy that has exhibited remarkable efficacy in combatting non-small cell lung cancer (NSCLC), particularly among individuals harbo···【more】
Article source：Captain MedicineRelease date：2024-07-09Recommended：356
Sotorasib, also known as AMG-510, is an orally bioavailable drug that falls under the category of selective KRAS G12C covalent inhibitors. By locking the KRAS G12C protein in an in···【more】
Article source：Captain MedicineRelease date：2024-07-09Recommended：409
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended：4252025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended：6082024-09-07
On May 28, 2026, AstraZeneca announced that its immunotherapy drug Imfinzi (durvalumab) in combinati···【more】
Recommended：702026-01-06
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended：3922025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended：4082025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended：4022025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended：4562025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended：3722025-01-12
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address: No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Name: Lucius
Telegram name: Vira
No.:0085253923643
Telegram name: Vira
No.:0085253923643
